drugset / Trial / NCT02368457

Management of Mandibular ORN: PENTO as Medical Treatment

NCT02368457

Phase 4 Completed 24 enrolled Hospital Vall d'Hebron
RandomizedParallel-groupOpen-labelTreatment

Summary

Mandibular osteoradionecrosis, despite its low incidence, remains being the most problematic and irreversible complication after head and neck radiotherapy with no medical treatment to limit or reduce symptoms. Different clinical trials have shown a significant scientific evidence that the treatment with pentoxifylline + tocopherol achieves a certain effectiveness in the treatment of the tissue fibrosis. This study proposes to use this drugs to determine if there is healing of mandibular osteoradionecrosis and/or a symptomatic improvement as well.

Timeline

Start
2016-02
Primary completion
2016-02
Completion
2018-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pentoxifylline Small molecule 800 mg Oral
Subject Vitamin E Other / unclassified 1000 iu Oral

Indications